News
-
New Phase III Data Shows Novartis JAK Inhibitor INC424 Significantly Reduced Disease Burden In Patients With Myelofibrosis
12/14/2011
Novartis recently announced additional results from two pivotal Phase III trials evaluating Janus kinase (JAK) inhibitor INC424 (ruxolitinib) in myelofibrosis.
-
New Data Confirms Novartis Drug Afinitor Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth
12/9/2011
The study findings, which represent an additional five months of follow-up, were presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), abstract #S3-7.
-
FDA: 35 Innovative New Drugs Approved In Fiscal Year 2011
11/4/2011
Over the past 12 months, the U.S. Food and Drug Administration approved 35 new medicines.
-
Novartis Achieves Strong Third Quarter Financial Performance And Pipeline Progress
10/28/2011
Novartis is announcing recently additional cost reduction activity, which will be executed over three to five years. Elements of the activity to include: reallocation of production within the Novartis network resulting in closure of two sites in Switzerland and one in Italy; restructuring the development organization largely in Switzerland and the US and relocating some research activities from Switzerland to the US.
-
Merck Announces Presentation Of Phase III Investigational Studies Evaluating DULERA® (Mometasone Furoate And Formoterol Fumarate Dihydrate) Inhalation Aerosol in Chronic Obstructive Pulmonary Disease (COPD)
10/27/2011
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from two 26-week investigational Phase III clinical studies evaluating the efficacy and safety of two dose strengths of DULERA® (mometasone furoate and formoterol fumarate dihydrate) in adults 40 years and older with moderate to very severe chronic obstructive pulmonary disease (COPD).
-
FDA Approves Remicade To Treat Ulcerative Colitis In Children 6 Years And Older
9/30/2011
The U.S. Food and Drug Administration recently approved Remicade (infliximab) to treat moderately to severely active ulcerative colitis (UC) in children 6 years and older who have had inadequate response to conventional therapy.
-
Novartis Drug Afinitor Effective In Patients With Non-Cancerous Kidney Tumors Associated With TSC In Phase III Trial
9/26/2011
A Phase III study of Afinitor (everolimus) tablets* in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors.
-
Roche Researchers Sequence Complete Genome Of Cynomolgus Monkey And Develop Novel Gene Expression Microarray For Drug Safety Assessment
9/23/2011
A team of researchers from Roche including scientists from Roche Pharma Research and Early Development and Roche NimbleGen, reported in Genome Research that they have generated the first draft genome sequence of the cynomolgus monkey (Macaca fascicularis) and developed a novel microarray design for in depth expression profiling for use in preclinical drug safety research.
-
HemoShear Awarded $4.3M NIH Grant To Develop Predictive Drug Database
9/2/2011
HemoShear, LLC, a biotechnology research company and leading developer of human and animal cell-based surrogate systems for discovery and assessment of new drug compounds, recently announced that it has been awarded up to $4.3M in a Phase II Small Business Innovation Research (SBIR) grant award from the National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH).
-
MakroCare, LSK Global Sign Alliance Agreement
8/23/2011
MakroCare, an international Drug Development and Commercialization services firm, and LSK Global, a Korean CRO headquartered in Seoul, recently announced the signing of an alliance agreement.
This website uses cookies to ensure you get the best experience on our website. Learn more